359 related articles for article (PubMed ID: 33226447)
1. Overriding sorafenib resistance via blocking lipid metabolism and Ras by sphingomyelin synthase 1 inhibition in hepatocellular carcinoma.
Lu H; Zhou L; Zuo H; Le W; Hu J; Zhang T; Li M; Yuan Y
Cancer Chemother Pharmacol; 2021 Feb; 87(2):217-228. PubMed ID: 33226447
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of sphingomyelin synthase (SMS) affects intracellular sphingomyelin accumulation and plasma membrane lipid organization.
Li Z; Hailemariam TK; Zhou H; Li Y; Duckworth DC; Peake DA; Zhang Y; Kuo MS; Cao G; Jiang XC
Biochim Biophys Acta; 2007 Sep; 1771(9):1186-94. PubMed ID: 17616479
[TBL] [Abstract][Full Text] [Related]
3. Suppression of sphingomyelin synthase 1 by small interference RNA is associated with enhanced ceramide production and apoptosis after photodamage.
Separovic D; Semaan L; Tarca AL; Awad Maitah MY; Hanada K; Bielawski J; Villani M; Luberto C
Exp Cell Res; 2008 May; 314(8):1860-8. PubMed ID: 18374917
[TBL] [Abstract][Full Text] [Related]
4. SMS overexpression and knockdown: impact on cellular sphingomyelin and diacylglycerol metabolism, and cell apoptosis.
Ding T; Li Z; Hailemariam T; Mukherjee S; Maxfield FR; Wu MP; Jiang XC
J Lipid Res; 2008 Feb; 49(2):376-85. PubMed ID: 17982138
[TBL] [Abstract][Full Text] [Related]
5. Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma.
Dietrich P; Gaza A; Wormser L; Fritz V; Hellerbrand C; Bosserhoff AK
Neoplasia; 2019 Mar; 21(3):257-268. PubMed ID: 30685691
[TBL] [Abstract][Full Text] [Related]
6. Novel Interconnections in Lipid Metabolism Revealed by Overexpression of Sphingomyelin Synthase-1.
Deevska GM; Dotson PP; Karakashian AA; Isaac G; Wrona M; Kelly SB; Merrill AH; Nikolova-Karakashian MN
J Biol Chem; 2017 Mar; 292(12):5110-5122. PubMed ID: 28087695
[TBL] [Abstract][Full Text] [Related]
7. Silencing
Zhu Q; Ren H; Li X; Qian B; Fan S; Hu F; Xu L; Zhai B
Aging (Albany NY); 2020 Nov; 12(22):22975-23003. PubMed ID: 33203790
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
[TBL] [Abstract][Full Text] [Related]
9. miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy.
Xu WP; Liu JP; Feng JF; Zhu CP; Yang Y; Zhou WP; Ding J; Huang CK; Cui YL; Ding CH; Zhang X; Lu B; Xie WF
Gut; 2020 Jul; 69(7):1309-1321. PubMed ID: 31727683
[TBL] [Abstract][Full Text] [Related]
10. Caspase-mediated inhibition of sphingomyelin synthesis is involved in FasL-triggered cell death.
Lafont E; Milhas D; Carpentier S; Garcia V; Jin ZX; Umehara H; Okazaki T; Schulze-Osthoff K; Levade T; Benoist H; Ségui B
Cell Death Differ; 2010 Apr; 17(4):642-54. PubMed ID: 19779494
[TBL] [Abstract][Full Text] [Related]
11. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
Wu J; Chai H; Li F; Ren Q; Gu Y
Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976
[TBL] [Abstract][Full Text] [Related]
12. Both sphingomyelin synthases SMS1 and SMS2 are required for sphingomyelin homeostasis and growth in human HeLa cells.
Tafesse FG; Huitema K; Hermansson M; van der Poel S; van den Dikkenberg J; Uphoff A; Somerharju P; Holthuis JC
J Biol Chem; 2007 Jun; 282(24):17537-47. PubMed ID: 17449912
[TBL] [Abstract][Full Text] [Related]
13. TFAM depletion overcomes hepatocellular carcinoma resistance to doxorubicin and sorafenib through AMPK activation and mitochondrial dysfunction.
Zhu Y; Xu J; Hu W; Wang F; Zhou Y; Xu W; Gong W; Shao L
Gene; 2020 Aug; 753():144807. PubMed ID: 32461017
[TBL] [Abstract][Full Text] [Related]
14. Sulfarotene, a synthetic retinoid, overcomes stemness and sorafenib resistance of hepatocellular carcinoma via suppressing SOS2-RAS pathway.
Qi F; Qin W; Zhang Y; Luo Y; Niu B; An Q; Yang B; Shi K; Yu Z; Chen J; Cao X; Xia J
J Exp Clin Cancer Res; 2021 Sep; 40(1):280. PubMed ID: 34479623
[TBL] [Abstract][Full Text] [Related]
15. Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain-Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma.
Leung CON; Tong M; Chung KPS; Zhou L; Che N; Tang KH; Ding J; Lau EYT; Ng IOL; Ma S; Lee TKW
Hepatology; 2020 Jul; 72(1):155-168. PubMed ID: 31610028
[TBL] [Abstract][Full Text] [Related]
16. HIF-1α-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib.
Song Z; Liu T; Chen J; Ge C; Zhao F; Zhu M; Chen T; Cui Y; Tian H; Yao M; Li J; Li H
Cancer Lett; 2019 Sep; 460():96-107. PubMed ID: 31247273
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis.
Li Y; Xia J; Shao F; Zhou Y; Yu J; Wu H; Du J; Ren X
Biochem Biophys Res Commun; 2021 Jan; 534():877-884. PubMed ID: 33162029
[TBL] [Abstract][Full Text] [Related]
18. Secretory NPC2 Protein-Mediated Free Cholesterol Levels Were Correlated with the Sorafenib Response in Hepatocellular Carcinoma.
Suk FM; Wang YH; Chiu WC; Liu CF; Wu CY; Chen TL; Liao YJ
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445279
[TBL] [Abstract][Full Text] [Related]
19. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
Wang M; Wang Z; Zhi X; Ding W; Xiong J; Tao T; Yang Y; Zhang H; Zi X; Zhou W; Huang G
Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246
[TBL] [Abstract][Full Text] [Related]
20. Long Noncoding RNA (lncRNA) Small Nucleolar RNA Host Gene 16 (SNHG16) Predicts Poor Prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.
Guo Z; Zhang J; Fan L; Liu J; Yu H; Li X; Sun G
Med Sci Monit; 2019 Mar; 25():2079-2086. PubMed ID: 30893293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
